{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-Cohort+5",
    "query": {
      "intervention": "Placebo-Cohort 5"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 616,
    "total_pages": 62,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-Cohort+5&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-16T06:48:00.413Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03221426",
      "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastric Cancer",
        "Gastroesophageal Junction Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "5-fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1007,
      "start_date": "2017-10-09",
      "completion_date": "2025-04-23",
      "has_results": true,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-09-16T06:48:00.413Z",
      "location_count": 14,
      "location_summary": "Duarte, California • New Haven, Connecticut • Washington D.C., District of Columbia + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03221426"
    },
    {
      "nct_id": "NCT05507515",
      "title": "A Phase 1 Study of ONO-2020 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ONO-2020",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ono Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2022-07-29",
      "completion_date": "2023-12-24",
      "has_results": false,
      "last_update_posted_date": "2024-04-09",
      "last_synced_at": "2026-09-16T06:48:00.413Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05507515"
    },
    {
      "nct_id": "NCT00990613",
      "title": "A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Huntington's Disease"
      ],
      "interventions": [
        {
          "name": "Dimebon IR",
          "type": "DRUG"
        },
        {
          "name": "Dimebon Transdermal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 19,
      "start_date": "2009-10",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2010-02-03",
      "last_synced_at": "2026-09-16T06:48:00.413Z",
      "location_count": 1,
      "location_summary": "Kalamazoo, Michigan",
      "locations": [
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00990613"
    },
    {
      "nct_id": "NCT02742779",
      "title": "A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "GDC-0310",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 95,
      "start_date": "2015-09-15",
      "completion_date": "2017-06-07",
      "has_results": false,
      "last_update_posted_date": "2020-02-20",
      "last_synced_at": "2026-09-16T06:48:00.413Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02742779"
    },
    {
      "nct_id": "NCT04948554",
      "title": "A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Sclerosis With and Without Interstitial Lung Disease"
      ],
      "interventions": [
        {
          "name": "MK-2225",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2023-03-10",
      "completion_date": "2023-10-18",
      "has_results": false,
      "last_update_posted_date": "2023-11-24",
      "last_synced_at": "2026-09-16T06:48:00.413Z",
      "location_count": 11,
      "location_summary": "La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 8 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04948554"
    },
    {
      "nct_id": "NCT04220801",
      "title": "A Study of Orally Administered ZM-H1505R to Evaluate Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Doses in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ZM-H1505R",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai Zhimeng Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 64,
      "start_date": "2020-02-17",
      "completion_date": "2020-11-18",
      "has_results": false,
      "last_update_posted_date": "2021-04-28",
      "last_synced_at": "2026-09-16T06:48:00.413Z",
      "location_count": 1,
      "location_summary": "Secaucus, New Jersey",
      "locations": [
        {
          "city": "Secaucus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04220801"
    },
    {
      "nct_id": "NCT05660265",
      "title": "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematologic Diseases",
        "Anaemia, Sickle Cell"
      ],
      "interventions": [
        {
          "name": "GSK4172239D",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 11,
      "start_date": "2023-08-26",
      "completion_date": "2025-09-22",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-09-16T06:48:00.413Z",
      "location_count": 6,
      "location_summary": "Miami, Florida • Tamarac, Florida • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Riverdale",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05660265"
    },
    {
      "nct_id": "NCT00031512",
      "title": "Pleconaril Enteroviral Sepsis Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Enterovirus Infection"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Pleconaril",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Days",
        "maximum_age": "15 Days",
        "sex": "ALL",
        "summary": "0 Days to 15 Days"
      },
      "enrollment_count": 61,
      "start_date": "2001-06-27",
      "completion_date": "2012-09-15",
      "has_results": false,
      "last_update_posted_date": "2024-02-05",
      "last_synced_at": "2026-09-16T06:48:00.413Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00031512"
    },
    {
      "nct_id": "NCT00499967",
      "title": "Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Genital Warts"
      ],
      "interventions": [
        {
          "name": "GS-9191 ointment",
          "type": "DRUG"
        },
        {
          "name": "GS-9191",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 202,
      "start_date": "2007-08",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2009-04-09",
      "last_synced_at": "2026-09-16T06:48:00.413Z",
      "location_count": 25,
      "location_summary": "Tucson, Arizona • Beverly Hills, California • Mission Viejo, California + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00499967"
    },
    {
      "nct_id": "NCT05181709",
      "title": "A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "Sodium Chloride",
          "type": "DRUG"
        },
        {
          "name": "NDV-HXP-S IN low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NDV-HXP-S IM low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NDV-HXP-S IN high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NDV-HXP-S IM high dose",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Sean Liu",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 35,
      "start_date": "2022-02-09",
      "completion_date": "2024-04-19",
      "has_results": false,
      "last_update_posted_date": "2025-04-17",
      "last_synced_at": "2026-09-16T06:48:00.413Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05181709"
    }
  ]
}